<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="LLC, Waltham, MA) also found increased overall infection risk with" exact="prednisone" post="&amp;gt;10Â mg/d in patients with rheumatoid arthritis (incidence rate"/>
 <result pre="of stay in oxygen requiring or ventilated patients treated with" exact="dexamethasone" post="6 mg daily for 10 days as compared with"/>
 <result pre="indicates that daily doses of systemic corticosteroids &amp;gt;10 mg of" exact="prednisone" post="equivalent are associated with an increased susceptibility to overall"/>
 <result pre="evidence from a large RCT suggests that the use of" exact="dexamethasone" post="reduces mortality in hospitalized COVID-19 patients. Further data are"/>
 <result pre="complications of systemic corticosteroid use in the setting of COVID-19." exact="Methotrexate" post="In clinical trials, methotrexate increased infection risk in patients"/>
 <result pre="use in the setting of COVID-19. Methotrexate In clinical trials," exact="methotrexate" post="increased infection risk in patients with rheumatoid arthritis (risk"/>
 <result pre="spondylitis, and scleroderma.20 Robust data for adverse events related to" exact="methotrexate" post="come from a recent clinical trial evaluating the efficacy"/>
 <result pre="from a recent clinical trial evaluating the efficacy of low-dose" exact="methotrexate" post="for the treatment of atherosclerosis in patients with cardiovascular"/>
 <result pre="infections.21 Conclusions A modestly increased risk of infection associated with" exact="methotrexate" post="has been suggested in some studies. Further data are"/>
 <result pre="studies. Further data are needed to understand the impact of" exact="methotrexate" post="on SARS-CoV-2 infection. Antimalarial drugs When used for their"/>
 <result pre="the treatment of SARS-CoV-2 infection. Although inÂ vitro data suggest" exact="chloroquine" post="and hydroxychloroquine both inhibit coronavirus,24,25 available clinical data do"/>
 <result pre="of SARS-CoV-2 infection. Although inÂ vitro data suggest chloroquine and" exact="hydroxychloroquine" post="both inhibit coronavirus,24,25 available clinical data do not suggest"/>
 <result pre="or clinical trial is cautioned against.31 Oral small molecules (azathioprine," exact="mycophenolate mofetil," post="and cyclosporine) Using claims data, Schneeweiss etÂ al32 examined"/>
 <result pre="opportunistic infections in patients with atopic dermatitis. Compared with methotrexate," exact="cyclosporine" post="A had a 58% higher risk of overall infection"/>
 <result pre="(adjusted RR, 1.58; 95% CI, 1.17-2.15). In the same study," exact="azathioprine" post="had double the infection risk (RR, 1.78; 95% CI,"/>
 <result pre="double the infection risk (RR, 1.78; 95% CI, 0.98-3.25), whereas" exact="mycophenolate mofetil" post="tripled the risk (RR, 3.31; 95% CI, 1.94-5.64). A"/>
 <result pre="study comparing patients with systemic lupus erythematosus newly treated with" exact="mycophenolate mofetil" post="or azathioprine found no differences in rates of serious"/>
 <result pre="with systemic lupus erythematosus newly treated with mycophenolate mofetil or" exact="azathioprine" post="found no differences in rates of serious infections.33 Studies"/>
 <result pre="potential in COVID-19 Some authors have suggested the use of" exact="cyclosporine" post="in the treatment of COVID-1937 based on its ability"/>
 <result pre="no ongoing clinical trials in patients with COVID-19. Conclusions Azathioprine," exact="mycophenolate mofetil," post="and cyclosporine A increase the risk of infection relative"/>
 <result pre="trials in patients with COVID-19. Conclusions Azathioprine, mycophenolate mofetil, and" exact="cyclosporine" post="A increase the risk of infection relative to reference"/>
 <result pre="caution and discussion with patients regarding starting or continuing therapy." exact="Apremilast" post="Long-term safety data from open-label extension studies in psoriasis"/>
 <result pre="a low risk of infection associated with the use of" exact="apremilast" post="and, therefore, low potential for harm in COVID-19 infection."/>
 <result pre="regarding Janus kinase (JAK) inhibitors comes from the use of" exact="tofacitinib" post="in rheumatoid arthritis. Analysis of the most recent tofacitinib"/>
 <result pre="of tofacitinib in rheumatoid arthritis. Analysis of the most recent" exact="tofacitinib" post="data from randomized controlled trials and long-term extension studies"/>
 <result pre="and nonselective JAK inhibitors.46, 47, 48 Therapeutic potential in COVID-19" exact="Ruxolitinib" post="(NCT04362137) and baricitinib (NCT04280705) are currently being evaluated in"/>
 <result pre="patients critically ill with COVID-19.10,49 Moreover, unlike tofacitinib, baricitinib and" exact="ruxolitinib" post="have demonstrated antiviral activity via inhibition of receptor-mediated endocytosis"/>
 <result pre="direct antiviral and anti-inflammatory effects in COVID-19, seemingly unique to" exact="ruxolitinib" post="and baricitinib. Taken together, there are insufficient data at"/>
 <result pre="similar overall rates of infections when rituximab is compared with" exact="methotrexate" post="plus placebo.60,61 Long-term observational studies also show that this"/>
 <result pre="8 (1.5) csDMARD MTX: 17 (20) 69 (63) 110 (21)" exact="Hydroxychloroquine" post="8 (9) N/A 0 Hospitalization 14 (16) 39 (35)"/>
 <result pre="systemic steroids should be tapered to daily doses &amp;lt;10Â mg" exact="prednisone" post="equivalent, if safe to do so. b.Patients on recurrent"/>
 <result pre="doses of systemic corticosteroids over high-dose regimens (eg, &amp;lt;20Â mg" exact="prednisone" post="equivalent daily for &amp;lt;2Â weeks); if needed for maintenance"/>
 <result pre="include mucous membrane blistering disorders. d.If possible, use alternatives to" exact="cyclosporine" post="and other agents requiring intensive toxicity/safety monitoring. Patients with"/>
 <result pre="agents (eg, apremilast, antimalarials, and retinoids), and anti-inflammatory medications (eg," exact="tetracycline" post="or macrolide class antibiotics). b.High-dose systemic corticosteroids should be"/>
 <result pre="in patients with newly diagnosed autoimmune diseaseMedicine (Baltimore)925201328529323982055 13GreenbergJ.D.ReedG.KremerJ.M.Association of" exact="methotrexate" post="and tumour necrosis factor antagonists with risk of infectious"/>
 <result pre="a systematic review and meta-analysisCrit Care23120199930917856 20IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of infection with" exact="methotrexate" post="therapy in inflammatory diseases: a systematic review and meta-analysisJ"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="acute respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 26PastickK.A.OkaforE.C.WangF.Review:" exact="hydroxychloroquine" post="and chloroquine for treatment of SARS-CoV-2 (COVID-19)Open Forum Infect"/>
 <result pre="syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 26PastickK.A.OkaforE.C.WangF.Review: hydroxychloroquine and" exact="chloroquine" post="for treatment of SARS-CoV-2 (COVID-19)Open Forum Infect Dis742020ofaa13032363212 27MahevasM.TranV.-T.RoumierM.No"/>
 <result pre="(COVID-19)Open Forum Infect Dis742020ofaa13032363212 27MahevasM.TranV.-T.RoumierM.No evidence of clinical efficacy of" exact="hydroxychloroquine" post="in patients hospitalized for COVID-19 infection with oxygen requirement:"/>
 <result pre="data to emulate a target trial [preprint]medRxiv202010.1101/2020.04.10.20060699 28GelerisJ.SunY.PlattJ.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19N Engl J Med3822520202411241832379955 29MagagnoliJ.NarendranS.PereiraF.Outcomes"/>
 <result pre="in hospitalized patients with Covid-19N Engl J Med3822520202411241832379955 29MagagnoliJ.NarendranS.PereiraF.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19 [preprint]medRxiv202010.1101/2020.04.16.20065920"/>
 <result pre="trialBMJ3692020m184932409561 31US Food and Drug AdministrationFDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
 <result pre="Food and Drug AdministrationFDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
 <result pre="Mofetil Renal Transplantation Study GroupA blinded, randomized clinical trial of" exact="mycophenolate mofetil" post="for the prevention of acute rejection in cadaveric renal"/>
 <result pre="coronavirus replication by cyclophilin inhibitorsViruses5520131250126023698397 40CrowleyJ.ThaÃ§iD.JolyP.Long-term safety and tolerability of" exact="apremilast" post="in patients with psoriasis: pooled safety analysis for â‰¥156"/>
 <result pre="(ESTEEM 1 and 2)J Am Acad Dermatol7722017310317.e128416342 41KavanaughA.GladmanD.D.EdwardsC.J.Long-term experience with" exact="apremilast" post="in patients with psoriatic arthritis: 5-year results from a"/>
 <result pre="PALACE 1â€&quot;3 pooled analysisArthritis Res Ther211201911831077258 42WollenhauptJ.LeeE.-B.CurtisJ.R.Safety and efficacy of" exact="tofacitinib" post="for up to 9.5â€‰years in the treatment of rheumatoid"/>
 <result pre="network meta-analysisClin Ther3812201626282641.e527889300 44StrandV.AhadiehS.DeMasiR.THU0211 Meta-analysis of serious infections with baricitinib," exact="tofacitinib" post="and biologic DMARDs in rheumatoid arthritis [abstract]Ann Rheum Dis76Suppl"/>
 <result pre="naÃ¯ve with active rheumatoid arthritis and an inadequate response to" exact="methotrexate" post="(Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))Ann"/>
 <result pre="observational studyArthritis Care Res (Hoboken)71820199931003 64JolyP.Maho-VaillantM.Prost-SquarcioniC.First-line rituximab combined with short-term" exact="prednisone" post="versus prednisone alone for the treatment of pemphigus (Ritux"/>
 <result pre="Care Res (Hoboken)71820199931003 64JolyP.Maho-VaillantM.Prost-SquarcioniC.First-line rituximab combined with short-term prednisone versus" exact="prednisone" post="alone for the treatment of pemphigus (Ritux 3): a"/>
</results>
